F. D. Tattersall

发表

Opportunities for the replacement of animals in the study of nausea and vomiting

P. Andrews, J. Rudd, A. Holmes, 2009, British journal of pharmacology.

In Vitro and in Vivo Properties of 3-tert-Butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA Receptor α5 Subtype-Selective Inverse Agonist

A. D. Rodrigues, K. Gingrich, G. Dawson, 2009, Journal of Pharmacology and Experimental Therapeutics.

In Vitro and in Vivo Properties of 3-tert-Butyl-7-(5-methylisoxazol-

A. D. Rodrigues, K. Gingrich, G. Dawson, 2009 .

Selective, Orally Active γ-Aminobutyric AcidA α5 Receptor Inverse Agonists as Cognition Enhancers

Desmond O'Connor, G. Dawson, J. Atack, 2004 .

5-Substituted-N-pyridazinylbenzamides as potent and selective LRRK2 inhibitors: Improved brain unbound fraction enables efficacy.

Zehong Wan, A. Reith, F. D. Tattersall, 2019, Bioorganic & medicinal chemistry letters.

Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret

F. D. Tattersall, A. Robichaud, I. Rodger, 1999, Neuropharmacology.

The novel NK1 receptor antagonist MK–0869 (L–754,030) and its water soluble phosphoryl prodrug, L–758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets

S. Tye, R. Hargreaves, F. D. Tattersall, 2000, Neuropharmacology.

The tachykinin NK1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret.

R. Hargreaves, F. D. Tattersall, R. Hill, 1993, European journal of pharmacology.

Enantioselective inhibition of ampomorphine-induced emesis in the ferret by the neurokinin1 receptor antagonist CP-99,994

R. Hargreaves, F. D. Tattersall, R. Hill, 1994, Neuropharmacology.

Emesis induced by cisplatin in the ferret as a model for the detection of anti-emetic drugs

B. Costall, R. Naylor, F. D. Tattersall, 1987, Neuropharmacology.

Evidence that decreased feeding induced by systemic injection of cholecystokinin is mediated by CCK-A receptors.

S. Iversen, C. Dourish, A. Ruckert, 1989, European journal of pharmacology.

Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.

J. Metzger, M. Maccoss, D. Macintyre, 1998, Journal of medicinal chemistry.

Detection of gender differences in rat lens proteins using 2‐D‐DIGE

J. Atack, M. Knowles, P. Guest, 2006, Proteomics.

The Actions of Fenfluramine and Interaction with 5‐HT3 Receptor‐Antagonists to Inhibit Emesis in the Ferret

B. Costall, R. Naylor, F. D. Tattersall, 1990, The Journal of pharmacy and pharmacology.

Reserpine, para-chlorophenylalanine and fenfluramine antagonise cisplatin-induced emesis in the ferret

B. Costall, R. Naylor, N. Barnes, 1988, Neuropharmacology.

Identification of 5‐HT3 recognition sites in the ferret area postrema

B. Costall, R. Naylor, N. Barnes, 1988, The Journal of pharmacy and pharmacology.

5-hydroxytryptamine m-receptor antagonism to prevent cisplatin-induced emesis

B. Costall, R. Naylor, F. D. Tattersall, 1986, Neuropharmacology.

Substituted fused bicyclic pyrrolizinones as potent, orally bioavailable hNK1 antagonists.

P. Davies, S. Boyce, M. Reibarkh, 2010, Bioorganic & medicinal chemistry letters.

Discriminative stimulus effects of tiagabine and related GABAergic drugs in rats

F. D. Tattersall, L. McDonald, P. Hutson, 2008, Psychopharmacology.

Gaboxadol, a selective extrasynaptic GABAA agonist, does not generalise to other sleep-enhancing drugs: A rat drug discrimination study

F. D. Tattersall, L. McDonald, P. Hutson, 2007, Neuropharmacology.